Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases

被引:431
作者
van Burik, JAH
Hare, RS
Solomon, HF
Corrado, ML
Kontoyiannis, DP
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA
[2] Adv Biol, New Hope, PA USA
[3] Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA
[4] Univ Minnesota, Minneapolis, MN USA
关键词
D O I
10.1086/500212
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis ( proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole ( 800 mg/day) program. The rate of success ( i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.
引用
收藏
页码:E61 / E65
页数:5
相关论文
共 18 条
  • [1] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
    Ascioglu, S
    Rex, JH
    de Pauw, B
    Bennett, JE
    Bille, J
    Crokaert, F
    Denning, DW
    Donnelly, JP
    Edwards, JE
    Erjavec, Z
    Fiere, D
    Lortholary, O
    Maertens, J
    Meis, JF
    Patterson, TF
    Ritter, J
    Selleslag, D
    Shah, PM
    Stevens, DA
    Walsh, TJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) : 7 - 14
  • [2] Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer
    Chamilos, G
    Marom, EM
    Lewis, RE
    Lionakis, MS
    Kontoyiannis, DP
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) : 60 - 66
  • [3] Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults
    Courtney, R
    Wexler, D
    Radwanski, E
    Lim, J
    Laughlin, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) : 218 - 222
  • [4] Oral bioavailability of posaconazole in fasted healthy subjects - Comparison between three regimens and basis for clinical dosage recommendations
    Ezzet, F
    Wexler, D
    Courtney, R
    Krishna, G
    Lim, J
    Laughlin, M
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (02) : 211 - 220
  • [5] Posaconazole as salvage therapy for zygomycosis
    Greenberg, RN
    Mullane, K
    van Burik, JAH
    Raad, I
    Abzug, MJ
    Anstead, G
    Herbrecht, R
    Langston, A
    Marr, KA
    Schiller, G
    Schuster, M
    Wingard, JR
    Gonzalez, CE
    Revankar, SG
    Corcoran, G
    Kryscio, RJ
    Hare, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) : 126 - 133
  • [6] Zygomycosis (mucormycosis): emerging clinical importance and new treatments
    Greenberg, RN
    Scott, LJ
    Vaughn, HH
    Ribes, JA
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (06) : 517 - 525
  • [7] Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections
    Herbrecht, R
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) : 612 - 624
  • [8] Toward more effective antifungal therapy: the prospects of combination therapy
    Kontoyiannis, DP
    Lewis, RE
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (02) : 165 - 175
  • [9] Zygomycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy:: A case-control observational study of 27 recent cases
    Kontoyiannis, DP
    Lionakis, MS
    Lewis, RE
    Chamilos, G
    Healy, M
    Perego, C
    Safdar, A
    Kantarjian, H
    Champlin, R
    Walsh, TJ
    Raad, II
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) : 1350 - 1360
  • [10] Zygomycosis in the 1990s in a tertiary-care cancer center
    Kontoyiannis, DP
    Wessel, VC
    Bodey, GP
    Rolston, KVI
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) : 851 - 856